Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice

Vaccine

Volumn 30, Issue 36, 2012, Pages 5382-5388

  Murata, Yoshihiko ^a,b   Catherman, Seana C ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

Attachment protein; Humoral immune response; Respiratory syncytial virus; Viral subtype

Indexed keywords

GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; INCUBATION TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEROLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; FEMALE; HUMANS; LUNG; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

EID: 84864015632     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.016     Document Type: Article

References (47)

1. Hall C.B., Weinberg G.A., Iwane M.K., Blumkin A.K., Edwards K.M., Staat M.A., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360(6):588-598.
2. Melero J.A., Garcia-Barreno B., Martinez I., Pringle C.R., Cane P.A. Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein. J Gen Virol 1997, 78(Pt 10):2411-2418.
3. Collins P.L., Graham B.S. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 2008, 82(5):2040-2055.
4. Walsh E.E., Brandriss M.W., Schlesinger J.J. Immunological differences between the envelope glycoproteins of two strains of human respiratory syncytial virus. J Gen Virol 1987, 68(Pt 8):2169-2176.
5. Walsh E.E., Hall C.B., Schlesinger J.J., Brandriss M.W., Hildreth S., Paradiso P. Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins. J Gen Virol 1989, 70(Pt 11):2953-2961.
6. Cane P.A., Thomas H.M., Simpson A.F., Evans J.E., Hart C.A., Pringle C.R. Analysis of the human serological immune response to a variable region of the attachment (G) protein of respiratory syncytial virus during primary infection. J Med Virol 1996, 48(3):253-261.
7. Cane P.A. Analysis of linear epitopes recognised by the primary human antibody response to a variable region of the attachment (G) protein of respiratory syncytial virus. J Med Virol 1997, 51(4):297-304.
8. Palomo C., Cane P.A., Melero J.A. Evaluation of the antibody specificities of human convalescent-phase sera against the attachment (G) protein of human respiratory syncytial virus: influence of strain variation and carbohydrate side chains. J Med Virol 2000, 60(4):468-474.
9. Lopez J.A., Bustos R., Orvell C., Berois M., Arbiza J., Garcia-Barreno B., et al. Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol 1998, 72(8):6922-6928.
10. Langedijk J.P., Middel W.G., Schaaper W.M., Meloen R.H., Kramps J.A., Brandenburg A.H., et al. Type-specific serologic diagnosis of respiratory syncytial virus infection, based on a synthetic peptide of the attachment protein G. J Immunol Methods 1996, 193(2):157-166.
11. Langedijk J.P., Brandenburg A.H., Middel W.G., Osterhaus A., Meloen R.H., van Oirschot J.T. A subtype-specific peptide-based enzyme immunoassay for detection of antibodies to the G protein of human respiratory syncytial virus is more sensitive than routine serological tests. J Clin Microbiol 1997, 35(7):1656-1660.
12. Jones L.P., Zheng H.Q., Karron R.A., Peret T.C., Tsou C., Anderson L.J. Multiplex assay for detection of strain-specific antibodies against the two variable regions of the G protein of respiratory syncytial virus. Clin Diagn Lab Immunol 2002, 9(3):633-638.
13. Murata Y., Lightfoote P.M., Biear J.N., Falsey A.R., Walsh E.E. Humoral response to the central unglycosylated region of the respiratory syncytial virus attachment protein. Vaccine 2010, 28(38):6242-6246.
14. Murata Y., Lightfoote P.M., Falsey A.R., Walsh E.E. Identification of and human serum reactogenicity to neutralizing epitopes within the central unglycosylated region of the respiratory syncytial virus attachment protein. Clin Vaccine Immunol 2010, 17(4):695-697.
15. Walsh E.E., Brandriss M.W., Schlesinger J.J. Purification and characterization of the respiratory syncytial virus fusion protein. J Gen Virol 1985, 66(Pt 3):409-415.
16. Walsh E.E., Hall C.B., Briselli M., Brandriss M.W., Schlesinger J.J. Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J Infect Dis 1987, 155(6):1198-1204.
17. Boukhvalova M.S., Yim K.C., Prince G.A., Blanco J.C. Methods for monitoring dynamics of pulmonary RSV replication by viral culture and by real-time reverse transcription-PCR in vivo: detection of abortive viral replication. Curr Protoc Cell Biol 2010, Chapter 26:Unit26.6.
18. Mok H., Lee S., Utley T.J., Shepherd B.E., Polosukhin V.V., Collier M.L., et al. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol 2007, 81(24):13710-13722.
19. Roder C., Krusat T., Reimers K., Werchau H. Purification of respiratory syncytial virus F and G proteins. J Chromatogr B Biomed Sci Appl 2000, 737(1-2):97-106.
20. Walsh E.E., Hruska J. Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J Virol 1983, 47(1):171-177.
21. Zhang W., Choi Y., Haynes L.M., Harcourt J.L., Anderson L.J., Jones L.P., et al. Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol 2010, 84(2):1148-1157.
22. Tripp R.A., Moore D., Jones L., Sullender W., Winter J., Anderson L.J. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol 1999, 73(9):7099-7107.
23. Murata Y., Lightfoote P.M., Rose R.C., Walsh E.E. Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres. Virol J 2009, 6:81.
24. Polack F.P., Hoffman S.J., Crujeiras G., Griffin D.E. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med 2003, 9(9):1209-1213.
25. Nguyen T.N., Power U.F., Robert A., Haeuw J.F., Helffer K., Perez A., et al. The respiratory syncytial virus g protein conserved domain induces a persistent and protective antibody response in rodents. PLoS One 2012, 7(3):e34331.
26. Kwilas S., Liesman R.M., Zhang L., Walsh E., Pickles R.J., Peeples M.E. Respiratory syncytial virus grown in Vero cells contains a truncated attachment protein that alters its infectivity and dependence on glycosaminoglycans. J Virol 2009, 83(20):10710-10718.
27. Garcia-Beato R., Martinez I., Franci C., Real F.X., Garcia-Barreno B., Melero J.A. Host cell effect upon glycosylation and antigenicity of human respiratory syncytial virus G glycoprotein. Virology 1996, 221(2):301-309.
28. Delgado M.F., Coviello S., Monsalvo A.C., Melendi G.A., Hernandez J.Z., Batalle J.P., et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009, 15(1):34-41.
29. Feng J., Gulati U., Zhang X., Keitel W.A., Thompson D.M., James J.A., et al. Antibody quantity versus quality after influenza vaccination. Vaccine 2009, 27(45):6358-6362.
30. Shinoff J.J., O'Brien K.L., Thumar B., Shaw J.B., Reid R., Hua W., et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis 2008, 198(7):1007-1015.
31. Routledge E.G., Willcocks M.M., Samson A.C., Morgan L., Scott R., Anderson J.J., et al. The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice. J Gen Virol 1988, 69(Pt 2):293-303.
32. Murawski M.R., McGinnes L.W., Finberg R.W., Kurt-Jones E.A., Massare M.J., Smith G., et al. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol 2010, 84(2):1110-1123.
33. Murphy B.R., Sotnikov A., Paradiso P.R., Hildreth S.W., Jenson A.B., Baggs R.B., et al. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 1989, 7(6):533-540.
34. Muelenaer P.M., Henderson F.W., Hemming V.G., Walsh E.E., Anderson L.J., Prince G.A., et al. Group-specific serum antibody responses in children with primary and recurrent respiratory syncytial virus infections. J Infect Dis 1991, 164(1):15-21.
35. Hendry R.M., Burns J.C., Walsh E.E., Graham B.S., Wright P.F., Hemming V.G., et al. Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J Infect Dis 1988, 157(4):640-647.
36. Blanco J.C.G., Richardson J.Y., Darnell M.E.R., Rowzee A., Pletneva L., Porter D.D., et al. Cytokine and chemokine gene expression after primary and secondary respiratory syncytial virus infection in cotton rats. J Infect Dis 2002, 185:1780-1785.
37. Schuurhof A., Bont L., Pennings J.L., Hodemaekers H.M., Wester P.W., Buisman A., et al. Gene expression differences in lungs of mice during secondary immune responses to respiratory syncytial virus infection. J Virol 2010, 84(18):9584-9594.
38. Johnson T.R., Johnson J.E., Roberts S.R., Wertz G.W., Parker R.A., Graham B.S. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J Virol 1998, 72(4):2871-2880.
39. Johnson T.R., Graham B.S. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5). IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol 1999, 73(10):8485-8495.
40. Bukreyev A., Yang L., Fricke J., Cheng L., Ward J.M., Murphy B.R., et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol 2008, 82(24):12191-12204.
41. Hendricks D.A., McIntosh K., Patterson J.L. Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus. J Virol 1988, 62(7):2228-2233.
42. Gorman J.J., McKimm-Breschkin J.L., Norton R.S., Barnham K.J. Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein. J Biol Chem 2001, 276(42):38988-38994.
43. Haynes L.M., Jones L.P., Barskey A., Anderson L.J., Tripp R.A. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol 2003, 77(18):9831-9844.
44. Harcourt J., Alvarez R., Jones L.P., Henderson C., Anderson L.J., Tripp R.A. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+T cell responses. J Immunol 2006, 176(3):1600-1608.
45. Oshansky C.M., Zhang W., Moore E., Tripp R.A. The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol 2009, 4(3):279-297.
46. Radu G.U., Caidi H., Miao C., Tripp R.A., Anderson L.J., Haynes L.M. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice. J Virol 2010, 84(18):9632-9636.
47. Escribano-Romero E., Rawling J., Garcia-Barreno B., Melero J.A. The soluble form of human respiratory syncytial virus attachment protein differs from the membrane-bound form in its oligomeric state but is still capable of binding to cell surface proteoglycans. J Virol 2004, 78(7):3524-3532.